Conclusions
Peritonsillar abscess is an extremely common ENT condition, and as such appropriate safe and effective management is critical. Current evidence suggests no clinical benefit for the routine administration of additional anaerobic cover (Metronidazole) to oral phenoxymethyl penicillin as part of the treatment of peritonsillar abscess. The use of single agent oral phenoxymethyl pencillin is effective and avoids the use of additional anaerobic cover reducing costs in healthcare systems, as well as reduced pressure to develop antimicrobial resistance.
Key Points